ArticleFrontiers in pharmacology2026
Andrographolide inhibits STAT1 expression and desensitizes interferon γ-induced priming in macrophage cells.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The herbal medicine Methods: The human monocytic cell line THP-1 was pre-activated with lipopolysaccharide (LPS) or phorbol 12-myristate 13-acetate (PMA). Murine and human primary macrophage cells were pre-activated with LPS. Results: In THP-1 cells, we showed that both LPS and PMA stimulated the expression of signal transducer and activator of transcription 1 (STAT1), the pivotal signaling module in type I and II IFNs; these responses were blunted by And at non-cytotoxic concentrations but not by Neo or Deo. In parallel, And significantly inhibited the priming effects of IFN-γ, including upregulation of the pro-inflammatory chemokine monocyte chemoattractant protein-1 and the NADPH oxidase subunit gp91phox. Mechanistically, we showed that the inhibitory effects of And on STAT1 expression in both LPS- and PMA-activated macrophages were, at least partly, attributable to the reduction in IFN-β expression, but not related to changes in IFN-β-induced activation of the transcription factor complex IFN-stimulated gene factor 3 or the stability of STAT1 mRNA. We confirmed the inhibitory effects of And on STAT1 expression and IFN-γ-induced priming in murine or human primary macrophages. Conclusion: Our results suggest that And may desensitize macrophage cells to IFN-γ-induced priming by inhibiting STAT1 expression. This effect of And may partly explain the multiple anti-inflammatory actions of this compound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.